Login
$ETON
$63.88 -$0.05 (0.08%) Live

$ETON SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
12 Nov 2026 Form 4: Erdogan-Trinkaus Ipek, Chief Commercial Officer

Received 3,500 shares by exercise or conversion ($54.1K) · Sold 3,500 shares ($236K)

10 Nov 2026 Form 4: Casamento Charles J, Director

Received 80,555 shares by exercise or conversion ($438K) · Sold 80,555 shares ($5.35M)

10 Nov 2026 144
10 Nov 2026 144
06 Nov 2026 SCHEDULE 13G/A
05 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

DEER PARK, Ill., November 5, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today ...

05 Nov 2026 8-K: Other Events

Eton Pharmaceuticals Announces Preliminary ET-700 Pilot Study Results Evaluating Copper Absorption Inhibition and Gastrointestinal Tolerability

02 Nov 2026 8-K: Other Events

Eton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic Spasms

14 Oct 2026 8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets

Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film

06 Oct 2026 Form 4: Krempa David, Chief Business Officer

Received 10,522 shares by exercise or conversion · Sold 4,166 shares ($229K)

06 Oct 2026 144
28 Sep 2026 8-K: Other Events

Eton Pharmaceuticals now holds exclusive commercialization rights for IMPAVIDO in the United States

31 Aug 2026 Form 4/A: Maier Paul V, Director

Received 62,500 shares by exercise or conversion ($280K) · Sold 50,000 shares ($2.95M) · Acquired 12,500 Employee Stock Option (Option Exercise/Conversion)

28 Aug 2026 Form 4: Maier Paul V, Director

Received 50,000 shares by exercise or conversion ($189K) · Sold 50,000 shares ($2.95M)

28 Aug 2026 144
24 Aug 2026 Form 4: Krempa David, Chief Business Officer

Received 25,000 shares by exercise or conversion ($183K) · Sold 25,000 shares ($1.63M)

24 Aug 2026 144
20 Aug 2026 Form 4: Brynjelsen Sean, Director

Sold 8,978 shares ($562K) · Sold 91,022 shares ($5.53M)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support